[
    {
     "kind": "calendar#event",
     "etag": "\"3267223267490000\"",
     "id": "hlsu0orscisaj8bfh1thk5pljc",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=aGxzdTBvcnNjaXNhajhiZmgxdGhrNXBsamMgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2021-10-07T13:00:33.000Z",
     "updated": "2021-10-07T13:00:33.745Z",
     "summary": "ACER Acer Therapeutics Inc. PDUFA",
     "description": "2022-06-05 The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 5, 2022. https://www.sec.gov/Archives/edgar/data/0001069308/000156459021050251/acer-ex991_24.htm",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2022-06-05"
     },
     "end": {
      "date": "2022-06-05"
     },
     "iCalUID": "hlsu0orscisaj8bfh1thk5pljc@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3289176012490000\"",
     "id": "057r67aoep4egpsmg89jl9mn34",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=MDU3cjY3YW9lcDRlZ3BzbWc4OWpsOW1uMzQgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-02-11T14:00:06.000Z",
     "updated": "2022-02-11T14:00:06.245Z",
     "summary": "REGN Sanofi - Aventis Groupe PDUFA",
     "description": "2022-06-09 The target action date for the FDA decision on this investigational use is June 9, 2022. https://www.globenewswire.com/news-release/2022/02/10/2382407/0/en/FDA-accepts-Dupixent-dupilumab-for-Priority-Review-in-children-aged-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis.html",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2022-06-09"
     },
     "end": {
      "date": "2022-06-09"
     },
     "iCalUID": "057r67aoep4egpsmg89jl9mn34@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3289867212030000\"",
     "id": "uut8v71159a6kr8m1dpj2jqf74",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=dXV0OHY3MTE1OWE2a3I4bTFkcGoyanFmNzQgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-02-15T14:00:05.000Z",
     "updated": "2022-02-15T14:00:06.015Z",
     "summary": "SNYNF Sanofi PDUFA",
     "description": "2022-06-09 The target action date for the FDA decision on this investigational use is June 9, 2022. https://www.sec.gov/Archives/edgar/data/0001121404/000119312522041110/d314853dex993.htm",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2022-06-09"
     },
     "end": {
      "date": "2022-06-09"
     },
     "iCalUID": "uut8v71159a6kr8m1dpj2jqf74@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3291595213398000\"",
     "id": "r983ibltu6sqhqpdq086rvgdak",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=cjk4M2libHR1NnNxaHFwZHEwODZydmdkYWsgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-02-25T14:00:06.000Z",
     "updated": "2022-02-25T14:00:06.699Z",
     "summary": "RYTM Rhythm Pharmaceuticals, Inc. PDUFA",
     "description": "2022-06-16 On February 23, the FDA notified the Company that the Prescription Drug User Fee Act (PDUFA) goal date has been revised to June 16, 2022. https://www.globenewswire.com/news-release/2022/02/24/2391401/0/en/Rhythm-Pharmaceuticals-Announces-FDA-Extension-of-Review-Period-for-IMCIVREE-setmelanotide-for-Patients-with-Bardet-Biedl-Syndrome-and-Alstr%C3%B6m-Syndrome.html",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2022-06-16"
     },
     "end": {
      "date": "2022-06-16"
     },
     "iCalUID": "r983ibltu6sqhqpdq086rvgdak@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3294014411680000\"",
     "id": "nj1rer3rmgnobaahdeeoebo7n4",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=bmoxcmVyM3JtZ25vYmFhaGRlZW9lYm83bjQgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-03-11T14:00:05.000Z",
     "updated": "2022-03-11T14:00:05.840Z",
     "summary": "TGTX TG Therapeutics, Inc. PDUFA",
     "description": "2022-06-25 FDA considered the updated OS data a substantial amendment and extended the PDUFA date for the BLA/sNDA to June 25, 2022. https://www.globenewswire.com/news-release/2022/03/10/2400913/8790/en/TG-Therapeutics-Announces-Scheduling-of-Planned-Oncologic-Drug-Advisory-Committee-Meeting.html",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2022-06-25"
     },
     "end": {
      "date": "2022-06-25"
     },
     "iCalUID": "nj1rer3rmgnobaahdeeoebo7n4@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3295044011172000\"",
     "id": "t2t0edv5gpe0cqro4hrso3k4sk",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=dDJ0MGVkdjVncGUwY3FybzRocnNvM2s0c2sgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-03-17T13:00:05.000Z",
     "updated": "2022-03-17T13:00:05.586Z",
     "summary": "ETON Eton Pharmaceuticals, Inc. PDUFA",
     "description": "2022-05-30 The application has been assigned a PDUFA date of May 30, 2022. https://www.sec.gov/Archives/edgar/data/0001710340/000149315222006990/form10-k.htm",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2022-05-30"
     },
     "end": {
      "date": "2022-05-30"
     },
     "iCalUID": "t2t0edv5gpe0cqro4hrso3k4sk@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3295735211460000\"",
     "id": "pv4u7vmpghf0i1ofh0qk174at4",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=cHY0dTd2bXBnaGYwaTFvZmgwcWsxNzRhdDQgNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-03-21T13:00:05.000Z",
     "updated": "2022-03-21T13:00:05.730Z",
     "summary": "RLFTY Relief Therapeutics Holding SA PDUFA",
     "description": "2022-06-05 The submission was accepted for review by the FDA with a Prescription Drug User Fee Act (PDUFA) approval decision action date of June 5, 2022. https://www.sec.gov/Archives/edgar/data/0001854078/000119312522079459/d225146d20fr12ba.htm",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2022-06-05"
     },
     "end": {
      "date": "2022-06-05"
     },
     "iCalUID": "pv4u7vmpghf0i1ofh0qk174at4@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
     "kind": "calendar#event",
     "etag": "\"3302992814114000\"",
     "id": "110bs08be669te5hj93ie32eu8",
     "status": "confirmed",
     "htmlLink": "https://www.google.com/calendar/event?eid=MTEwYnMwOGJlNjY5dGU1aGo5M2llMzJldTggNWRzbzg1ODk0ODZpcnRqNTNzZGtyNGg2ZWtAZw&ctz=America/Los_Angeles",
     "created": "2022-05-02T13:00:07.000Z",
     "updated": "2022-05-02T13:00:07.057Z",
     "summary": "BMY BRISTOL MYERS SQUIBB PDUFA",
     "description": "2022-06-24 The FDA assigned a PDUFA goal date of June 24, 2022. http://www.businesswire.com/news/home/20220429005060/en/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results-for-2022",
     "creator": {
      "email": "fdatracker@gmail.com"
     },
     "organizer": {
      "email": "5dso8589486irtj53sdkr4h6ek@group.calendar.google.com",
      "displayName": "PDUFA",
      "self": true
     },
     "start": {
      "date": "2022-06-24"
     },
     "end": {
      "date": "2022-06-24"
     },
     "iCalUID": "110bs08be669te5hj93ie32eu8@google.com",
     "sequence": 0,
     "reminders": {
      "useDefault": false
     },
     "eventType": "default"
    },
    {
        "kind": "calendar#event",
        "etag": "\"3307312842280000\"",
        "id": "7asg3vlinnkcuqjjk5thn4s6qg",
        "status": "confirmed",
        "htmlLink": "https://www.google.com/calendar/event?eid=N2FzZzN2bGlubmtjdXFqams1dGhuNHM2cWcgZXZnb2hvdm0ybTN0dXZxYWtkZjRoZmVxODRAZw&ctz=America/Los_Angeles",
        "created": "2022-05-27T13:00:21.000Z",
        "updated": "2022-05-27T13:00:21.140Z",
        "summary": "MRNA Moderna, Inc. FDA AdCom",
        "description": "2022-06-14 Agenda\nThe meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing platform. The committee will meet in open session to discuss the following:  On June 14, 2022, under Topic 1, the committee will meet in open session to discuss amending the EUA of the Moderna COVID-19 mRNA vaccine to include the administration of the primary series to children and adolescents 6 years through 17 years of age.  On June 15, 2022, under Topic II, the committee will meet in open session to discuss amending the EUA of the Moderna COVID-19 mRNA vaccine to include the administration of the primary series to infants and children 6 months through 5 years of age, and also to discuss amending the EUA of the Pfizer-BioNTech COVID-19 mRNA vaccine to include the administration of the primary series to infants and children 6 months through 4 years of age.. https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-14-15-2022-meeting-announcement",
        "creator": {
         "email": "fdatracker@gmail.com"
        },
        "organizer": {
         "email": "evgohovm2m3tuvqakdf4hfeq84@group.calendar.google.com",
         "displayName": "Adcom",
         "self": true
        },
        "start": {
         "date": "2022-06-14"
        },
        "end": {
         "date": "2022-06-14"
        },
        "iCalUID": "7asg3vlinnkcuqjjk5thn4s6qg@google.com",
        "sequence": 0,
        "reminders": {
         "useDefault": false
        },
        "eventType": "default"
       }
   ]